Category Archives: leadership

Biomedical Innovation in Trouble

By Jill Wechsler | Published: July 27, 2012

The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy makers propose funding cuts for the National Institutes of Health (NIH). This bleak picture of the “state of biomedical innovation” was painted by [...]

Also posted in Biotech, FDA, R&D, Technology, healthcare | Tagged Amgen, Francis Collins, innovation, National Center for Advancing Translational Sciences, NIH, Warburg Pincus | 3 Comments

Missed Opportunities in Rare Disease

By Ben Comer | Published: July 20, 2012

At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment.

Also posted in Corporate Responsibility, Events, Market Access, Regulatory, patient compliance, patient education | Tagged CBI, orphan diseases, Orphan Drugs, rare diseases, REMS | Leave a comment

Can Emerging Markets Emerge Fast Enough?

By Ben Comer | Published: July 12, 2012

The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?

Also posted in Emerging Markets, Europe, Global, Market Access, Strategy, pricing | Tagged Drug spend, Emerging Markets, Global, IMS, Outlook, pharmerging markets | Leave a comment

The Yin and Yang of the Court Decision on HCR

By Guest Blogger | Published: June 29, 2012

by Tom Norton If you’re like me, you probably bounded out of bed on Thursday morning, took in all the news you could find about the Supreme Court and healthcare reform…and then you waited. You waited patiently for the biggest legal call in American healthcare history. And then, there it was. What did we learn? Well, first, [...]

Also posted in FDA, Legal, Market Access, Regulatory, Strategy, healthcare | Tagged Barack Obama, Healthcare Refrom, Medicaid, Patient Protection and Affordable Care Act, Supreme Court | 1 Comment

BIO 2012: The Case for Collaboration

By Ben Comer | Published: June 19, 2012

Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”

Also posted in Biotech, Europe, Events, FDA, Global, IP, People, R&D, Regulatory, Strategy, Technology, healthcare | Tagged BIO, CEO, Chris Viehbacher, collaboration, conference, innovation, life sciences, Sanofi | Leave a comment